Related Experiment Video

Updated: Jul 4, 2025

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.1K

Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy

Dantong Sun1,2, Haili Qian3, Junling Li4

  • 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Journal of Biomedical Science
|January 28, 2024
PubMed

Insights

MDM2 amplification is linked to poor outcomes in cancer patients treated with immune checkpoint inhibitors (ICIs), potentially causing hyperprogressive disease. MDM2 inhibitors show promise for combination therapy to improve treatment efficacy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biomarker Discovery

Background:

  • MDM2 is an oncogene implicated in malignancy progression, promoting metastasis and proliferation.
  • MDM2 influences the tumor immune microenvironment (TIME), contributing to immune evasion and tolerance.
  • Pancancer studies identify MDM2 as a poor prognostic biomarker for immune checkpoint inhibitor (ICI) therapy.

Purpose of the Study:

  • To investigate the role of MDM2 in cancer progression and response to immunotherapy.
  • To explore the therapeutic potential of targeting MDM2 in combination with ICIs.

Main Methods:

  • Review of pancancer studies analyzing MDM2 status in relation to ICI treatment outcomes.
  • Examination of MDM2's mechanistic roles in oncogenesis and immune modulation.
  • Evaluation of preclinical data on MDM2 inhibitors and their impact on TIME.

Main Results:

  • MDM2 amplification is associated with increased risk of hyperprogressive disease (HPD) post-ICI therapy.
  • MDM2 promotes tumor growth, metastasis, and immune suppression.
  • MDM2 inhibitors demonstrate ability to alleviate TIME suppression.

Conclusions:

  • MDM2 is a critical factor in cancer progression and immune evasion during ICI treatment.
  • Targeting MDM2 with inhibitors offers a promising strategy for combination therapy with anticancer immunotherapy.
  • Further research into MDM2-targeted therapies could lead to improved patient survival rates.
Keywords:
Anticancer immunotherapyMDM2MalignanciesTumor immune microenvironment

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K